News for BioNTech SE (0A3M.L)

Summary Pfizer Inc (PFE) and BioNTech SE have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommend

Summary BioNTech SE (BNTX), in collaboration with Pfizer, announced on July 25, 2025, that the European Medicines Agency's Committee for Medicinal Products for

The European Medicines Agency's CHMP has recommended the marketing authorization for Pfizer (PFE) and BioNTech's (BNTX) LP.8.1-adapted COVID-19 vaccine in

Summary BioNTech SE (BNTX), a global leader in next-generation immunotherapy, announced it will release its financial results for the second quarter of 2025 on

BioNTech (BNTX) to release Q2 2025 financial results on August 4, 2025. A conference call and webcast are scheduled for 8:00 a.m. EDT (2:00 p.m. CEST) t

MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE ( BNTX, ”œBioNTech” or ”œthe Company”) will announce its financial results for the second qu

MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, 'BioNTech” or 'the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

BioNTech's Chief Strategy Officer, Ryan Richardson, announces resignation effective September 30. Analyst price targets suggest a potential upside of 19

Summary BioNTech SE (BNTX) announced on July 17, 2025, that Ryan Richardson will step down as Chief Strategy Officer and Board Director at affiliated companies

BioNTech (BNTX) has revealed that Ryan Richardson will be departing his role as Chief Strategy Officer effective September 30. Richardson will also step down fr

MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) ”“ BioNTech SE ( BNTX, ”œBioNTech” or ”œthe Company”) announced today that Ryan Richardson will step down

MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) - BioNTech SE (Nasdaq: BNTX, 'BioNTech” or 'the Company”) announced today that Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, 2025, and as a Board Director at affiliated companies of the BioNTech Group by mutual agreement to pursue new professional opportunities. The process of transitioning his responsibilities to other members of the Management Board is underway, ensuring a smooth handover.

On July 16, 2025, B of A Securities analyst Tazeen Ahmad maintained a "Buy" rating for BioNTech (BNTX). However, the analyst adjusted the 12-month price target

On July 10, 2025, Morgan Stanley's analyst Terence Flynn issued an update on BioNTech (BNTX), maintaining an

On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s investigational bispecific antibody...

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the ”œM&A Class Action Firm”), has recov

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. is contemplating whether to prompt a government advisory panel to review vaccines containing alum

H.C. Wainwright has reduced its price target for BioNTech (BNTX) from $145 to $138, while maintaining a Buy rating on the stock. This adjustment comes after Bio